ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Cardiovascular"

  • Abstract Number: 0140 • ACR Convergence 2024

    Estimation of 10-year Cardiovascular (CV) Risk and Traditional CV Risk Factors Distribution in Patients with Rheumatoid Arthritis from Three Italian Macro-areas

    Fabiola Atzeni1, Fabio Cacciapaglia2, Elena Bartoloni Bocci3, Matteo Piga4, Garifallia Sakellariou5, Ombretta Viapiana6, Alessandro Giollo7, SIMONE PARISI8, Maria Sole Chimenti9, Ennio Giulio Favalli10, Addolorata Corrado11, Eleonora Celletti12, Ivan Giovannini13, Serena Guiducci14, Elisa Gremese15, Andreina Manfredi16, Francesca Romana Spinelli17 and Gian Luca Erre18, and "Cardiovascular Obesity and Rheumatic DISeaases" Study Group of the Italian Society of Rheumatology, 1University of Messina, Italy, Messina, Italy, 2Rheumatology Unit DiMePRe-J, University and AOU Policlinico of Bari, Italy, Bari, Italy, 3Rheumatology Unit. Department of Medicine, Perugia, Perugia, Italy, 4Rheumatology Unit - Department of Medical Sciences and Public Health, University of Cagliari, Monserrato, Italy, 5Department of Internal Medicine and Medical Therapy, University of Pavia, and Istituti Clinici Scientifici Maugeri IRCCS Pavia,, Pavia, Italy, 6Rheumatology Unit, University of Verona, Verona, Italy, 7Azienda Ospedale Università Padova, Padova, Padua, Italy, 8Rheumatology Unit, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, TURIN, Italy, 9Rheumatology, Allergology and Clinical Immunology, University of Rome Tor Vergata, Roma, Italy, 10ASST Gaetano Pini-CTO, Milan, Lombardia, Italy, 11Rheumatology Unit, University of Foggia, Foggia, Italy, 12Medical Clinic, SS. Annunziata Hospital of Chieti, Department of Medicine and Science of Aging, G. D'Annunzio University of Chieti-Pescara, Chieti, Italy, 13Azienda Sanitaria Universitaria Friuli Centrale, Udine, Udine, Italy, 14University of Florence, Pistoia, Italy, 15Catholic University of the Sacred Heart, Rome, Rome, Italy, 16University of Modena and Reggio Emilia, Modena, 17Sapienza University of Rome, Rome - Italy, Roma, Rome, Italy, 18Rheumatology Unit - University of Sassari, Sassari, Italy

    Background/Purpose: Geographic origins can significantly impact people’s health, particularly in Italy, where regional health disparities are among the most pronounced [1]. Rheumatoid arthritis (RA) is…
  • Abstract Number: 0478 • ACR Convergence 2024

    Skin Sodium in Patients with Rheumatoid Arthritis: Association with Blood Pressure and Disease Activity

    Carolina Ramirez, Annette Oeser, Rachelle Crescenzi, C. Michael Stein and Michelle Ormseth, Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Sodium is stored in tissues such as the skin where it may contribute to development and progression of autoimmune diseases and hypertension through activation…
  • Abstract Number: 0761 • ACR Convergence 2024

    An Observational Study of Lifetime Prevalence of Thromboembolism Among Patients with Giant Cell Arteritis

    Ioannis Koulas1, Nikolaos Tsaftaridis2, Ivana Ilic3, Jack Jnani4, Alex Spyropoulos1 and Lara El Khoury5, 1Feinstein Institutes for Medical Research/Northwell Health, Manhasset, 2Feinstein Institutes for Medical Research/Northwell Health, Manhasset, NY, 3Northwell, Brooklyn, NY, 4Department of Medicine/Northwell Health, Manhasset, 5Division of Rheumatology/Northwell Health, Great Neck, NY

    Background/Purpose: Studies indicating a higher incidence rate of stroke and venous thromboembolism (VTE) among patients with giant cell arteritis (GCA) hint at a possible association between…
  • Abstract Number: 1115 • ACR Convergence 2024

    Rheumatic Disease Patients: Assessment of Hydroxychloroquine’s Effects on QTc Intervals with Weight Based Dosing (RAISE-QT) Study

    Joseph Azzam1, Johny Fares1, nithin Pusapati1, Swamy Venuturupalli2 and Daniel Wallace3, 1Cedars Sinai, Los Angeles, 2Attune Health, Beverly Hills, CA, 3Cedars Sinai Medical Center, Studio City, CA

    Background/Purpose: The primary objective was to investigate subjects with rheumatic disease (Systemic Lupus Erythematosus (SLE), Sjogrens disease (SjD), and Rheumatoid Arthritis (RA)) who initiated HCQ…
  • Abstract Number: 1521 • ACR Convergence 2024

    Contemporary Lupus Nephritis Treatment and Outcomes Among Patients with Systemic Lupus Erythematosus in the United States

    Aakash Patel1, Baijun Zhou2, Hyon K. Choi3 and April Jorge1, 1Massachusetts General Hospital, Harvard Medical School, Boston, MA, 2Massachusetts General Hospital, Boston, MA, 3Massachusetts General Hospital, Lexington, MA

    Background/Purpose: Lupus nephritis (LN) is associated with excess morbidity and mortality, with prior studies finding a disproportionate impact on Black patients. We sought to determine…
  • Abstract Number: 1981 • ACR Convergence 2024

    Assessing Major Adverse Cardiovascular Events (MACE) Risk in Common Rheumatology Treatments

    Manush Sondhi1, Samina Hayat2, Kinza Muzaffar1 and Sarwat Umer1, 1LSU HEALTH SHREVEPORT, Shreveport, LA, 2Louisiana State University Shreveport, Shreveport, LA

    Background/Purpose: This study aims to evaluate the risk of major cardiovascular events (MACE) associated with common rheumatology medications.Methods: We conducted a retrospective pharmacovigilance analysis using…
  • Abstract Number: 2459 • ACR Convergence 2024

    Use of Nailfold Capillaroscopy as a Predictor of Cardiovascular Events and Mortality in Systemic Sclerosis

    Carlos Valera-Ribera1, Javier Narvaez-García2, Joaquín Lacasa-Molina3, Laura Perea-Galera4, Alida Taberner-Cortés3, Paula Andrea Mencio-Viana3, Patricia Leon-Torralba3, Adrián Mayo-Juanatey3, Pablo Andújar-Brazal3, Ignacio Vázquez Gómez5, Desamparados Ybáñez-García3, Àngels Martínez-Ferrer6, Elia Valls-Pascual7, Montserrat Robustillo Villarino8 and JUAN JOSE ALEGRE SANCHO3, 1Hospital Doctor Peset, Valéncia, Comunidad Valenciana, Spain, 2Hospital Universitario de Bellvitge, Barcelona, Spain, 3Hospital Universitario Doctor Peset, Valencia, Spain, 4Hospital Universitario Doctor Peset, Valencia, 5H. U. Dr. Peset, Valencia, 6Hospital Universitario Dr Peset Valéncia, Valéncia, Spain, 7Hospital General de Valencia, Valencia, Comunidad Valenciana, Spain, 8Hospital Universitario La Plana, Villarreal, Spain

    Background/Purpose: Systemic sclerosis (SSc) is a disease with high morbidity and mortality. Nailfold capillaroscopy (NFC) is a widely used method for its diagnosis. Our objective…
  • Abstract Number: 0141 • ACR Convergence 2024

    The Effect of Systemic Immunosuppressive Therapies on Cardiovascular Risk in Psoriatic Arthritis Patients

    Melody Esmaeili1, Linh Truong2, Nicole Ridolfi3, Eugenia Chen4 and Maida wong5, 1University of California, Irvine, Orange, CA, 2University of California, Los Angeles, Los Angeles, CA, 3University of California, Irvine, Newport Beach, CA, 4Long Beach VA Hospital, Irvine, CA, 5Long Beach VA Hospital, Los Angeles, CA

    Background/Purpose: Evidence demonstrates an increased prevalence of atherosclerotic cardiovascular disease (ASCVD) among psoriatic arthritis (PsA) patients. However, the relationship between immunosuppressive therapies and the development of ASCVD remains unclear.…
  • Abstract Number: 0482 • ACR Convergence 2024

    Endothelial Dysfunction and QRISK3 in Rheumatoid Arthritis

    Vanshika Sabharwal1 and Ashit Syngle2, 1MMDU, Mullana, Ambala India and Healing Touch city clinic, Chandigarh, India, Chandigarh, Chandigarh, India, 2Healing Touch City Clinic, Chandigarh, Chandigarh, India

    Background/Purpose: CV disease is leading cause of morbidity and mortality in RA, largely due to endothelial dysfunction.1. Endothelial function is barometer of total cardiovascular risk while…
  • Abstract Number: 0807 • ACR Convergence 2024

    Evaluating Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus (SLE) and SLE Subgroups: Additional Risks Associated with Cardiovascular Events

    Rashmi Dhital1, Rebecca Baer2, Kenneth Kalunian3 and Christina Chambers4, 1UC San Diego, Brentwood, TN, 2UC San Diego, San Diego, 3University of California San Diego, La Jolla, CA, 4University of California, San Diego, La Jolla, CA

    Background/Purpose: Systemic Lupus Erythematosus (SLE) presents substantial risks for both maternal cardiovascular events (CVEs) and adverse pregnancy outcomes, yet, the influence of maternal CVEs on…
  • Abstract Number: 1119 • ACR Convergence 2024

    Treatment Outcomes of TNF-α Inhibitors in Cardiac Sarcoidosis

    Kailey Singh1, Harrison Zucker1, Alice Kwon2, Audrey Liu3, Josephine Rini1, Elena Katzap4, Sonali Narain5 and Galina Marder6, 1Northwell Health at Northshore/Long Island Jewish, Manhasset, 2Northwell Health at Northshore/Long Island Jewish, Bayside, NY, 3Loma Linda University, Loma Linda, CA, 4Northwell Health, Great NY, NY, 5Northwell Health, Great Neck, NY, 6Donald and Barbara Zucker School of Medicine at Hofstra/ Northwell, Great Neck, NY

    Background/Purpose: Management of cardiac sarcoidosis remains controversial. Our study aimed to describe our experience using tumor necrosis factor-α-inhibitors (aTNF) in cardiac sarcoidosis treatment.Methods: This is a…
  • Abstract Number: 1557 • ACR Convergence 2024

    Estimation of Cardiovascular Risk in Patients with Systemic Sclerosis – Accuracy of Tools Based on SCORE and Its Modifications Compared to Ultrasound Examination of Subclinical Atherosclerosis

    Sabína Oreská1, Aneta Prokopcová2, Hana Storkanova1, Jaroslav Kudlicka3, Vladimir Tuka4, Ondrej Mikes4, Zdislava Krupickova4, Martin Satny4, Eva Chytilova4, Jan Kvasnicka4, Maja Spiritovic5, Barbora Hermankova6, Petr Cesak7, Marian Rybar8, Karel Pavelka9, Ladislav Šenolt2, Radim Becvar1, Jiří Vencovský2, Michal Vrablik4 and Michal Tomcik1, 1Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, 2Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 3Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, 43rd Department of Internal Medicine, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, 5Institute of Rheumatology, Prague, Czech Republic, Prague, 6Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, 7Department of Human Movement Laboratory, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, 8Department of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University in Prague, Kladno, Czech Republic, Kladno, 9Institute of Rheumatology and Charles University, Praha, Czech Republic

    Background/Purpose: Patients with systemic sclerosis (SSc) have increased cardiovascular (CV) risk due to accelerated atherosclerosis (ATS) caused by systemic inflammation, and vascular impairment. To date,…
  • Abstract Number: 2009 • ACR Convergence 2024

    Risk of Incident Gout and Cardiovascular Events Within 120 Days of Incident Gout with the Use of Insulin Glargine, Glucagon-like Peptide-1 Receptor Agonists, or Sodium-Glucose Cotransporter-2 Inhibitors in Veterans with Type 2 Diabetes

    Amara Sarwal1, Augustine Takyi1, Guo Wei1, McKenna Nevers1, Ravinder Singh1, Sydney Hartsell1, Robert Boucher1, Niharika Katkam1, Akhil Chakravartula1, Jincheng Shen1, Srinivasan Beddhu1 and Naomi Schlesinger2, 1University of Utah, VA Salt Lake City Health Care System, Salt Lake City, UT, 2University of Utah, Salt Lake City, UT

    Background/Purpose: Previous studies compared the risk of gout with sodium-glucose cotransporter-2 inhibitors (SGLT2i) versus glucagon-like peptide-1 receptor agonists (GLP1-RA), including exendin-4 based GLP1-RA (exenatide and lixisenatide). Synthetic…
  • Abstract Number: 2499 • ACR Convergence 2024

    Description of Patients with Kawasaki Disease Shock Syndrome at a Large Tertiary Center

    Jessica Nguyen1, Danielle Guffey2, Andrea Ramirez1, Jamie Lai3, Tiphanie Vogel1, S. Kristen Sexson Tejtel1, Cagri Yildirim-Toruner4 and Marietta De Guzman1, 1Baylor College of Medicine, Houston, TX, 2Baylor College of Medicine, Houston, 3Baylor College of Medicine, The Woodlands, TX, 4Baylor College of Medicine/ Texas Children's Hospital, Houston, TX

    Background/Purpose: Kawasaki disease shock syndrome (KDSS) is a phenotype of Kawasaki disease (KD) associated with higher rates of refractory KD (RKD) and coronary artery aneurysms…
  • Abstract Number: 0143 • ACR Convergence 2024

    Behavioral Factors and Chronic Conditions Associated with Rheumatoid Arthritis, KNHANES 2010 to 2021

    GI HYUN MYUNG and Juwon Lim, Seoul National University Hospital, Seoul, Republic of Korea

    Background/Purpose: Rheumatoid arthritis (RA) is associated with multiple genetic and environmental factors. In terms of environmental, dietary and lifestyle factors, there have been discrepancies on…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 31
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology